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Abstract
Background: This study aimed to compare myocardial protective effects of anaesthesia with intravenous infusion
of propofol versus inhalation of sevoflurane in patients undergoing heart valve replacement surgery with
cardiopulmonary bypass.
Methods: Seventy-six patients undergoing valve replacement with cardiopulmonary bypass were randomly
assigned to propofol or sevoflurane anesthesia during the surgery, respectively. For assessing myocardial injury,
cardiac troponin I (cTnI) and creatine kinase isozyme (CK-MB) were determined before induction (T0), 0.5 h (T1) and
3 h (T2) after aortic unclamping, and 24 h (T3) and 48 h (T4) after surgery. The concentrations of interleukin (IL)-6
and IL-10 as the systemic inflammatory and anti-inflammatory markers were also measured at above time points.
Results: In the sevoflurane group, the plasma concentrations of cTnI and CK-MB from Tl to T4 and the levels of IL-6
and IL-10 from T1 to T2 were lower than those in the propofol group. Moreover, a higher ratio of automatic heart
beat recovery and a shorter length of intensive care unit or hospital stay were found in the sevoflurane group
comparing with the propofol group.
Conclusion: Sevoflurane anaesthesia produced more prominent myocardial protection and attenuated
inflammatory response than propofol anaesthesia in patients with valve replacement surgery under
cardiopulmonary bypass, resulting in shorter ICU and in-hospital stay.
Retrospective clinical trial registration: Identified as ChiCTR-IOR-16009979 at http://www.chictr.org.cn/.
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Background
Cardiac surgical procedures unavoidably produce myo-
cardial cell injury, which may originate from myocardial
ischemia reperfusion, cardiopulmonary bypass (CPB), or
operative procedure, etc. [1–5]. Previous studies
suggested that both modern inhaled anesthetics (such as
isoflurane or sevoflurane) and intravenous anesthetic
propofol have the effect of myocardial preservation in
different degree [6–9]. Nevertheless, most of those
studies were performed in patients undergoing coronary
artery bypass grafting (CABG), while few studies in non-
CABG patients. Furthermore, high quality meta-analyses
in adult cases have showed controversial or contradic-
ting results [10–15]. In this study, we compared the
cardioprotective effect of anesthesia with intravenous
propofol and inhaled sevoflurane in patients undergoing
mitral, aortic or tricuspid valve replacement surgery.
Plasma cardiac troponin-I (cTnI) and creatine kinase
isozyme (CK-MB) were used as the primary markers of
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myocardial cell injury, and the levels of interleukin (IL)-
6 and IL-10 within 48 h after operation were used as the
systemic inflammatory and anti-inflammatory markers.
Methods
Experimental protocol
This prospective, randomized control study was approved
by our institutional ethics committee (Affiliated Hospital
of North Sichuan Medical College, Nanchong, China).
The written informed consents were obtained from 76
patients scheduled for open-heart cardiac surgery (uni-
valve replacement of mitral, aortic or tricuspid valve due
to stenosis or/and regurgitation) with cardiopulmonary
bypass. All patients were American Society of Anaesthe-
siologists physical status II-IV, aged between 40 and
65 years, New York Heart Association classification of
cardiac function II-III, ejection fraction greater than 40%,
no history of nervous system diseases. The patients were
randomly assigned to the sevoflurane group or the propo-
fol group with equal size according to computer-
generated randomization. The sevoflurane group and the
propofol group were anaesthetized by inhaled sevoflurane
or by infusion of propofol during the entire operative
procedure, respectively. Exclusion criteria included hyper-
tensive disease, coronary artery disease, diabetes, chronic
obstructive pulmonary disease, infective endocarditis,
hematogenic and immune systemic disease, perioperative
steroid therapy, and contraindications for using propofol
or sevoflurane.
Primary and secondary end-points
The primary end-points were the changes of cTnI and
CK-MB values from the beginning of anaesthesia to 48 h
after operation. Secondary end-points included the
changes of IL-6 and IL-10 during and within 48 h after
operation, the ratio of automatic heart beat recovery, the
requirements of intraoperative vasoactive agents, and
short-term clinical outcomes (time of mechanical venti-
lation, length of ICU/hospital stay, awareness during




Patients were premedicated with intramuscular pheno-
barbital sodium 100 mg and anisodamine 10 mg 30 min
preoperative. In the operating room, all patients were
routinely monitored for the electrocardiogram, pulse
oxygen saturation, end-tidal carbon dioxide pressure,
invasive radial arterial pressure, central venous pressure
and auditory evoked potential index (AEPi) with a PM-
9000 express multifunctional monitor (Mindray Medical
International Limited, Shenzhen, China). Transesopha-
geal echocardiograph and urine output were also
monitored. In the two groups, anaesthesia was induced
with midazolam 0.1–0.2 mg kg−1 and fentanyl 10 μg kg
−1. Vecuronium 0.15 mg kg−1 was given to facilitate tra-
cheal intubation. Mechanical ventilation was controlled
using 100% oxygen with a tidal volume of 6–8 ml kg−1.
A normal end tidal carbon dioxide pressure (35–
45 mmHg) was obtained by adjusted the respiratory fre-
quency at 12–16 breaths/min. In the sevoflurane group,
Anaesthesia was maintained by inhaled sevoflurane (1–
5%), and fentanyl (5–10 μg kg−1) and vecuronium
0.1 mg kg−1 boli as needed. During CPB, sevoflurane
was administered through the oxygenator. The depth of
anaesthesia before, during and after CPB was controlled
at AEPi 30–40, 15–30 and 30–40 by adjusted inhaled
sevoflurane concentration, respectively [16–19]. In the
propofol group, anaesthesia was maintained with propo-
fol at a infusion rate of 3–10 mg · kg−1 · h−1, and fentanyl
(5–10 μg kg−1) and vecuronium 0.1 mg kg−1 boli as
needed; the depth of anaesthesia before, during and after
CPB was also controlled at AEPi 30–40, 15–30 and 30–
40 by adjusted the infusion rate of propofol, respectively.
Surgery and cardiopulmonary bypass
The cold cardioplegia solution was prepared by magne-
sium sulfate 2.5 g, potassium chloride 2 g, and sodium
bicarbonate 0.5 g in 500 ml physiologic saline, and
administered into the aortic root every 30 min. The CPB
procedure and surgical techniques under moderate
hypothermia (28–32 °C) were standardized. The two
groups of patients were operated by the same group of
cardiac surgeons. The CPB prime volume, 1000–
1500 ml calculated by patient’s weight, contained lactate
Ringer’s solution, hetastarch, mannitol, heparin and
blood (depending on the expected pump haematocrit).
The perfusion pressure (50–70 mmHg) was maintained
by a continuous non-pulsatile blood-flow rate of 2.0–
2.5 l min−1 m−2 during CPB. All patients were weaned
off CPB by the support of small doses of dopamine and
norepinephrine. The patients were withdrawn from the
study if the CPB time was less 30 min or over 120 min
or repeated CPB was more than two times.
Hemodynamic data
Global hemodynamic data (mean arterial pressure
[MAP], central venous pressure [CVP], cardiac output)
were recorded just before the start of surgery, before the
start of CPB (pre-CPB), 15 min after the end of CPB,
and at the end of the operation. Five consecutive beats
were averaged.
Intensive care unit management
All patients were continuously supported by mechanical
ventilation in the thoracic surgical intensive care unit
(ICU) postoperatively. For analgesia and sedation,
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fentanyl 50–100 μg and midazolam 0.1 mg kg−1 were
intravenous bolus according to clinical needs. Patients
were extubated when they could maintain adequate
spontaneous respiration and required minimal oxygen
support. The amount of vasoactive drugs were recorded
during operation and after admission to the ICU. Intra-
operative awareness by operative questionnaire and the
time of mechanical ventilation, as well as the length of
ICU/hospital stay were documented.
Laboratory measurements
Blood samples (4 ml) were collected from the peripheral
or central venous line at just before induction (T0),
30 min (T1) and 3 h (T2) after aortic unclamping, and
24 h (T3) and 48 h (T4) after operation. One ml of 4 ml
blood sample was used to measure the hematocrit (Hct),
and the rest 3 ml blood sample was used to measure the
biomarkers of myocardial injury (cTnI, CK-MB), the in-
flammatory factor (IL-6) and anti-inflammatory factor (IL-
10) in our hospital clinical chemistry department. The
concentrations of cTnI and CK-MB were determined by
immunochemistry analytic method (reagent kit provided
by Abbott Lab, US), and the lower detection limit is
0.01 ng ml−1. IL-6 and IL-10 were measured using
enzyme-linked immunosorbent assay (reagent kit pro-
vided by Rapid Bio, USA), and the detection thresholds
were 9 pg ml−1 and 15 pg ml−1, respectively. To avoid the
effect of hemodilution on experiment data, the following
formula was used to calibration: theoretical value =mea-
sured value × (baseline Hct value/measured Hct value).
The baseline Hct was measured before induction.
Statistical analysis
A sample size of 70 cases would have a power of 95% to
detect a difference in the level of cTnI of 2 ng ml−1 as a
primary end-point using a two-sample t-test with 0.05 two-
sided significance level [11, 20, 21]. Patient characteristics
were compared with an unpaired t test and Fisher exact test
where appropriate. Both biochemical serum markers and
hemodynamic data were compared using a two-way ana-
lysis of variance techniques for repeated measurements in
each group and between the two groups. All data were ana-
lyzed with the statistical package SPSS19.0 (SPSS Inc, Chi-
cago, IL, USA) and expressed as mean (standard deviation)
unless otherwise stated and statistical significance was ac-
cepted at P < 0.05.
Results
The study included a total of 76 patients undergoing
valve replacement surgery with CPB. In the sevoflurane
group, one patient was excluded from this study due to
the CPB duration exceeding 120 min. In the propofol
group, two patients were excluded from this study
because one case needed repetitive CPB and the other
one’s CPB duration exceeded 120 min. The two groups
were comparable with respect to sex, age, weight, types
of surgery, CPB time, aortic clamp time, arrest time,
total administered dose of fentanyl (midazolam), and the
incidence of intraoperative awareness. However, com-
pared with the propofol group, less consuming doses of
vasoactive drugs, a higher ratio of automatic heart beat
recovery, a shorter length of ICU or hospital stay were
found in the sevoflurane group (Table 1). The changes
Table 1 Patient characteristics
Patient characteristics Propofol (n = 37) Sevoflurane (n = 36)
Preoperative data
Age (yr) 50.7 (6.6) 50.5 (6.4)
Weight (kg) 54.5 (7.9) 56.5 (11.8)
Sex (M/F) 18 / 19 16 / 20
ASA class II–IV II–IV
EF (%) 57.2 (5.6) 55.9 (5.4)
Types of surgery (n, %)
Replacement of mitral valve 15 (40) 14 (39)
Replacement of aortic valve 9 (24) 10 (28)
Replacement of tricuspid valve 4 (10) 4 (11)
Replacement of mitral valve
and shaping of tricuspid valve
9 (24) 8 (22)
Intraoperative data
Operating time (min) 198 (28) 183 (34)
CPB time (min) 95 (18) 96 (17)
Aortic clamp time (min) 62 (21) 64 (18)






Propofol (mg) 857.3 (166.5) 0
Sevoflurane (MAC hour) 0 4.6 (0.9)
Fentanyl (mg) 2.0 (0.2) 2.1 (0.3)
Midazolam (mg) 20.6 (2. 9) 22.8 (3.0)
Dopamine (mg) 57.3 (13.5) 45.9 (15.1)*
Nitroglycerin (μg) 130.3 (50.2) 102.2 (34.5)*








ICU stay (hr) 48.6 (3.7) 42.3 (3.5)*
Hospital stay (d) 16 (13–19) 12 (9–15)*
Values are expressed as mean (SD) or median (range). *P < 0.05 vs the value of
propofol group
EF Ejection fraction, ASA class American Society of Anaesthesiologists physical
status classification, MAC minimum alveolar concentration, MAC hr inhaled
anaesthetic concentration/MAC × inhaled time (hr)
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of AEPi in the two groups were kept similar (Fig. 1).
Both mean arterial pressure and cardiac output after
CPB were decreased in the propofol group but not in
the sevoflurane group (Table 2). Central venous pressure
was kept stable throughout in both groups. A similar
trend of cTnI, CK-MB, IL-6 or IL-10 in the two groups
was observed: the biomarkers increased very fast 30 min
after aortic unclamping and peaked 3 h later, then
started to decrease gradually. cTnI and CK-MB
remained increased even at 48 h after operation, while
IL-6 and IL-10 returned to baseline levels. However, the
respective levels in the sevoflurane group were always
lower than those in the propofol group in corresponding
time points (Table 3).
Discussion
Our study shows that patients receiving sevoflurane an-
aesthesia have better myocardial protective effect than
patients receiving propofol anaesthesia for the heart
valve replacement surgery under CPB. In the present
study, both the cTnI and CK-MB were used as the sensi-
tive and specific indicators of myocardial cell injury [22–
25]. In order to meet the needs of a better comparability
of cardioprotection between the two groups, a similar
depth of anaesthesia was monitored by AEP index
through adjusting the inhaled sevoflurane concentration
or the infusion rate of propofol in different periods of
surgical procedure (pre-, during and post-bypass) (Fig. 1),
and the proportions of valve replacement in both groups
are also similar (Table 1). Although surgical procedure
itself - as heart valve replacement implicates direct myo-
cardial injury and the leak of cTnI and CK-MB, a lower
level of cTnI or CK-MB was found in the sevoflurane
group. It implicates sevoflurane may alleviate the myo-
cardial cell injury to some degree. Our present results
are well coincident with previous studies by using in-
haled anaesthetics in CABG or paediatric cardiac surgery
[1, 2, 4, 20, 26, 27]. Studies have reported that the cardi-
oprotection mechanism of inhaled anesthetics such as,
volatile anesthetics open intracellular KATP channels, ac-
tivate adenosine receptors, and inhibit Na+/K+ pump [1,
8, 28, 29]. Studies have also reported that the cardiopro-
tection mechanism of propofol is related to its anti-in-
flammatory, immunomodulatory and antioxidant
properties [21, 30, 31]. Nevertheless, many studies,
such as some prospective randomized controlled trials
[10–13, 32] and observational study [14] in adult
patients indicated some contradicting results on the
cardioprotection between volatile and non volatile
agents. We speculate the reasons of these contradict-
ory results may be related to the differences of
patients’ conditions, anaesthesia protocols, surgery
types and procedures, etc. For example, volatile
anaesthetics or propofol were administered in any
combination of the pre-, during and post-bypass
period in previous studies. In Bignami’s study, no
difference was found in the myocardial protective
effect between sevoflurane and propofol [32], which
may partly due to no administration of sevoflurane
during CPB in the inhalation anesthesia group. On
the contrary, in our present study, both sevoflurane
and propofol were administered throughout the
operative procedure, which may provide an optimal
cardioprotection. In addition, the cardioprotective
effect produced by sevoflurane or propofol may
related to the concentration used in some degree. La-
boratory investigations reported 1.0 MAC of volatile
anaesthetics provides beneficial effect to cardiac
injury. Lower concentrations of less than 0.75 MAC
often showed no effect, whereas higher concentrations
Fig. 1 The changes of auditory evoked potential index (AEPi) in the two groups. The changes of AEPi were kept similar in pre-anaesthesia, intubation,
pre-CPB, during CPB, after CPB and the end of operation between the two groups, respectively. CPB = Cardiopulmonary bypass
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of more than 1.5 MAC did not result in further
protective effect [1, 33, 34]. In this study, AEPi was
used to conduct the regulation of inhaled sevoflurane
concentration or the infusion rate of propofol in
different surgical procedures. No intraoperative aware-
ness occurred in the two groups implied that the
administered sevoflurane concentration (1–5%) and
the infusion rate of propofol (3–8 mg kg−1 h−1) were
reasonable. However, the use of sevoflurane was asso-
ciated with a significant increase in the ratio of auto-
matic heart beat recovery after aorta unclamping, a
more stable mean arterial pressure (Table 2) and a
less inotropic support (Table 1) during operation. It
indicated the depression of cardiac function in the
sevoflurane group was less than that in the propofol
group. In addition, that a significant reduction in the
time of mechanical ventilation, length of ICU stay
and the time to hospital discharge can make patients
with valve replacement benefit from the use of sevo-
flurane throughout the entire procedure.
It is well-known that CPB and operative procedure
often evoke a nonseptic systemic inflammatory reaction,
with the potential risk of postoperative cardiac dysfunc-
tion [29, 30, 35]. The anti-inflammatory potential of
sevoflurane has been reported in lots of CABG surgeries
under CPB [36, 37]. When compared with the systemic
delivery of sevoflurane, Kortekaas and co-authors in
their study found that the intramyocardial delivery of
sevoflurane can more strongly attenuate the systemic in-
flammatory response after CPB [38]. The results of this
study also indicated sevoflurane possesses a strong prop-
erty to depress the systemic inflammatory response in
patients with valve replacement surgery. In this study,
the lower plasma levels of prime proinflammatory cyto-
kine IL-6 and anti-inflammatory cytokine IL-10 in the
sevoflurane group during 48 h after surgery, indicates
that sevoflurane anaesthesia attenuated postoperative
cytokine response vs. propofol anaesthesia. This effect,
on top of sevoflurane cardiac protective effect, may have
independently contributed to the enhanced recovery of
the patients.
Our study has several limitations. Firstly, although the
patients could be randomly assigned to the sevoflurane
group and the propofol group, the anaesthesiologists
could not be blinded to the anaesthetic technique used
in each group. However, the experimenters who
collected the postoperative data and the laboratory staff
were blinded to the randomization. Secondly, the data
resulted from a relatively small number of patients.
Therefore, more patients were needed for further study.
Thirdly, in some degree, our present study lacked a
clinically important positive outcome, which may due to
a less myocardial ischemia or injury in non-CABG cases
Table 2 Perioperative Hemodynamic Data
Parameter Start of surgery Pre-CPB Post-CPB End of surgery
MAP (mmHg)
Propofol 82 (3) 76 (5) 68 (4)* 71 (4)*
Sevoflurane 79 (4) 77 (5) 76 (3)# 80 (3)#
CVP (mmHg)
Propofol 11 (3) 12 (2) 11 (3) 12 (3)
Sevoflurane 12 (3) 11 (3) 12 (2) 12 (2)
Cardiac output (l/min)
Propofol 5.7 (0.7) 5.2 (0.8) 4.6 (0.7)* 4.7 (0.5)*
Sevoflurane 5.5 (0.8) 5.4 (0.9) 5.6 (0.6)# 5.4 (0.6)#
Data are mean (SD). * Different compared to before the start of surgery
(P < 0.05). # Different between propofol and sevoflurane (P < 0.05)
MAPmean arterial pressure, CVP central venous pressure, CPB
cardiopulmonary bypass
Table 3 Perioperative markers of myocardial injury and systemic inflammation
Marker T0 T1 T2 T3 T4
cTnI (ng/ml)
Propofol 0.01 (0.02) 18.26 (9.67)# 26.66 (9.10)# 13.71 (6.14)# 8.72 (4.83)#
Sevoflurane 0.02 (0.02) 10.17 (6.63)#* 15.17 (8.73)#* 9.00 (6.43)#* 4.62 (3.40)#*
CK-MB (u/l)
Propofol 0.87 (0.50) 47.73 (9.30)# 86.12 (7.50)# 31.79 (6.29)# 14.35 (4.31)#
Sevoflurane 0.88 (0.60) 28.54 (7.69)#* 61.29 (8.80)#* 20.60 (7.84)#* 8.28 (2.16)#*
IL-6 (pg/ml)
Propofol 15.86 (4.45) 36.89 (6.71)# 59.69 (7.53)# 25.80 (6.15)# 17.14 (5.17)
Sevoflurane 13.91 (5.00) 27.87 (7.83)#* 42.67 (8.89)#* 22.64 (6.92)# 15.44 (4.54)
IL-10 (pg/ml)
Propofol 19.07 (4.75) 56.72 (8.36)# 73.73 (7.44)# 28.35 (6.90)# 20.58 (7.56)
Sevoflurane 16.79 (4.74) 38.24 (7.90)#* 54.29 (8.08)#* 23.70 (6.51)# 18.88 (5.50)
Data are given as mean (SD). T0 = before induction, T1 = 30 min after aortic unclamping, T2 = 3 h after aortic unclamping, T3 = 24 h after surgery, T4 = 48 h after
surgery. # P < 0.01 vs. T0;
*P < 0.05 vs. the corresponding value in the propofol group
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than that in CABG cases, or a effective myocardial protec-
tion either produced by sevoflurane or propofol. Another
limitation was that a relatively short CPB time was
selected. However, the cardioprotective effect of sevoflur-
ane or propofol in those patients with multi-valve replace-
ment or longer CPB time needs a further multi-center
clinical study.
Conclusions
In conclusion, patients receiving sevoflurane for uni-valve
replacement surgery under CPB had significantly lower
postoperative release of cTnI or CK-MB, and lighter in-
flammatory response than patients receiving propofol for
the same procedure. Our findings suggest the administra-
tion of inhaled sevoflurane throughout the entire proced-
ure can produce more significant myocardial protection
and resulted in shorter ICU and in-hospital stay which
may have further economic implications than the intra-
venous infusion of propofol.
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